Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients

Kenichi Nishimuraa Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, JapanCorrespondence[email protected]
View further author information

Ryoki Haraa Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, JapanView further author information

Hiroaki Umebayashib Department of Rheumatology and Infectious Disease, Miyagi Children’s Hospital, Sendai, JapanView further author information

Syuji Takeic School of Medical and Dental Sciences Pediatrics, Kagoshima University Graduate, Kagoshima, JapanView further author information

Naomi Iwatad Department of Infection and Immunology, Aichi Children’s Health and Medical Center, Obu, JapanView further author information

Tomoyuki Imagawae Department of Infection and Immunology, Kanagawa Children’s Medical Center, Yokohama, JapanView further author information

Masaki Shimizuf Department of Pediatrics, Kanazawa University Hospital, Kanazawa, JapanView further author information

Minako Tomiitag Department of Pediatrics, Pediatric Allergy and Rheumatology Center, National Hospital Organization Shimoshizu National Hospital, Chiba, JapanView further author information

Noriko Sekoh Novartis Pharma KK, Tokyo, JapanView further author information

Tetsuji Kitawakih Novartis Pharma KK, Tokyo, JapanView further author information

Shumpei Yokotai Children’s Intractable Disease Rheumatism Center, Fuji Toranomon Orthopedics Hospital, Shizuoka, JapanView further author information

show all

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date